منابع مشابه
Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit.
Immunosuppressive therapy has been shown to either improve or, more frequently, enhance the development of atherosclerosis. We tested the effect of mycophenolate mofetil (MMF), an inhibitor of nucleotide synthesis widely used in transplant therapy, in diet-induced atherosclerosis in the rabbit. Two groups (n=10 each) of New Zealand White (NZW) rabbits were fed a 1% cholesterol diet for 12 weeks...
متن کاملTherapeutic monitoring of mycophenolate mofetil.
M ycophenolate mofetil (MMF) has become the single most used immunosuppressant in solid-organ transplantation. Despite a well-documented relationship and efficacy (in terms of acute rejection prophylaxis) and exposure to mycophenolic acids (MPA) as measured by area under the curve (AUC), excellent results have been achieved using a fixed-dosage regimen. In the past several years, there has been...
متن کاملMycophenolate mofetil for localized scleroderma
Commentary Systemic sclerosis is one of the rheumatic diseases that is associated with the worst prognosis. Systemic sclerosis is divided into localized and systemic forms. Localized scleroderma comprises four subtypes, namely morphea, generalized morphea, linear scleroderma and en coup de saber, and is more commonly encountered in children. Although conversion into systemic sclerosis is very u...
متن کاملSevere Enteropathy From Mycophenolate Mofetil
The adverse effects of mycophenolate mofetil on the colon are well known. However, isolated small intestinal involvement resulting in diarrhea and severe weight loss is infrequently reported in the literature. We present the case of a 45-year-old woman on mycophenolate mofetil following renal transplant, who presented with abdominal pain and weight loss. An esophagogastroduodenoscopy and colono...
متن کاملIntravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.
An intravenous (i.v.) formulation of mycophenolate mofetil (MMF; CellCept, Roche Pharmaceuticals, Inc., Palo Alto, CA) that will enable its administration to patients unable to tolerate oral medication is available. Two separate studies, an open-labeled pharmacokinetic (PK) study and a double-blind safety study, were performed. Within 24 h after transplant, 153 (safety study) and 45 (PK study) ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology Science and Practice
سال: 2009
ISSN: 1995-4492,1995-4484
DOI: 10.14412/1995-4484-2009-588